Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress

Genetics Investing

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for the first quarter of 2018 and recent business progress. As quoted in the press release: “We are encouraged by the initial launch of LUXTURNA™ (voretigene neparvovec-rzyl). We are pleased that three …

As quoted in the press release:

“We are encouraged by the initial launch of LUXTURNA™ (voretigene neparvovec-rzyl). We are pleased that three patients were treated with LUXTURNA in the first quarter as we remain focused on working closely with treatment centers and payers to support timely access to the product,” said Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics. “Additionally, we progressed our pipeline of investigational gene therapies, including continuing to enroll our Phase 1/2 clinical trial of SPK-8011 in hemophilia A and advancing our preparations for a Phase 3 clinical trial of SPK-8011.”

Click here to read the full press release.

disease financial results gene therapy genetic disease patients phase 3 clinical trial pipeline spark therapeutics therapeutics Genetics Investing